About Us

Arcturus Therapeutics a global late-stage messenger RNA medicines and vaccines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.

Our team has extensive experience in the discovery and development of mRNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely position us to catalyze the next generation of mRNA medicines.

https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Large.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/Arcturus_Lobby_Small.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_large.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/22ArctP750_thumb.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1244fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/ArcBuilding_Final.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_external_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF-scaled.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/18arct1055fxF_230.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-exterior.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main_office_exterior_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/main-visual-office-interior-tag-line.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/building_tagline_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab286fxFNLLo_thumbnail.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo-scaled-1.jpg
https://arcturusrx.com/wp-content/uploads/2023/01/20arctlab206fxFNLLo_thumbnail.jpg
News & Events
March 4, 2013
Arcturus Therapeutics Begins Operations in Janssen Labs
READ MORE
May 8, 2013
Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board
READ MORE
September 27, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
READ MORE
October 26, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
READ MORE
November 1, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
READ MORE
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
READ MORE
November 9, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
READ MORE
December 12, 2022
CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
READ MORE
December 13, 2022
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
READ MORE
December 19, 2022
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
READ MORE
January 31, 2023
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
READ MORE
March 28, 2023
Arcturus Therapeutics Announces Fourth Quarter 2022 Financial Update and Pipeline Progress
READ MORE
April 26, 2023
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 9, 2023
READ MORE
May 9, 2023
Arcturus Therapeutics Announces First Quarter 2023 Financial Update and Pipeline Progress
READ MORE
June 1, 2023
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
READ MORE
July 24, 2023
Arcturus Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update on August 7, 2023
READ MORE
August 7, 2023
Arcturus Therapeutics Announces Second Quarter 2023 Financial Update and Pipeline Progress
READ MORE
August 14, 2023
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded $115 Million in Grants from the Japanese Government
READ MORE
August 17, 2023
Arcturus Therapeutics to Attend Upcoming Investor Conferences
READ MORE
September 5, 2023
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
READ MORE
September 19, 2023
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
READ MORE
September 26, 2023
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
READ MORE